Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2016 1
2018 2
2019 5
2020 5
2021 5
2022 8
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab Vedotin in urothelial cancer.
Alt M, Stecca C, Tobin S, Jiang DM, Sridhar SS. Alt M, et al. Among authors: jiang dm. Ther Adv Urol. 2020 Dec 27;12:1756287220980192. doi: 10.1177/1756287220980192. eCollection 2020 Jan-Dec. Ther Adv Urol. 2020. PMID: 33447264 Free PMC article. Review.
Targeting the FGFR Pathway in Urothelial Carcinoma: the Future Is Now.
Peng J, Sridhar S, Siefker-Radtke AO, Selvarajah S, Jiang DM. Peng J, et al. Among authors: jiang dm. Curr Treat Options Oncol. 2022 Sep;23(9):1269-1287. doi: 10.1007/s11864-022-01009-4. Epub 2022 Aug 13. Curr Treat Options Oncol. 2022. PMID: 35962938 Review.
Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis.
Sayyid RK, Klaassen Z, Berlin A, Roy S, Brandão LR, Bernardino R, Chavarriaga J, Jiang DM, Spratt DE, Fleshner NE, Wallis CJD. Sayyid RK, et al. Among authors: jiang dm. BJU Int. 2023 Dec;132(6):619-630. doi: 10.1111/bju.16130. Epub 2023 Jul 28. BJU Int. 2023. PMID: 37461140 Review.
Lack of Evidence Does Not Equal Lack of Benefit: Neoadjuvant Chemotherapy and Trimodality Therapy in Selected Patients with Muscle-Invasive Bladder Cancer : In response to: Dirk Böhmer and Arne Grün. Lacking Evidence to Recommend Neoadjuvant Chemotherapy and Definitive Radiotherapy in Muscle-Invasive Bladder Cancer.
Jiang DM, Chung P, Kulkarni GS, James ND, Sridhar SS. Jiang DM, et al. Curr Oncol Rep. 2021 Mar 3;23(3):36. doi: 10.1007/s11912-021-01035-9. Curr Oncol Rep. 2021. PMID: 33660142 No abstract available.
35 results